Patents Assigned to Angion Biomedica Corp.
-
Patent number: 11542256Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable salts thereof, wherein Cy1, Cy2, Cy3, R, R1, R2, R3, A1 and A2 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which inhibiting ROCK1, ROCK2, or ROCK1/2 has a therapeutically useful role.Type: GrantFiled: August 31, 2018Date of Patent: January 3, 2023Assignee: Angion Biomedica Corp.Inventors: An-Hu Li, Dibyendu Dana, Dong Sung Lim, Satishkumar Gadhiya, Dawoon Jung, Prakash Narayan, Quaisar Ali, Swarnalatha Paka, Itzhak D. Goldberg
-
Patent number: 11504359Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.Type: GrantFiled: August 2, 2019Date of Patent: November 22, 2022Assignee: Angion Biomedica Corp.Inventors: Bijoy Panicker, Rama K. Mishra, Dong Sung Lim, Lambertus J. W. M. Oehlen, Dawoon Jung
-
Patent number: 11459319Abstract: The present invention provides compounds having the general structural formula (I) (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.Type: GrantFiled: September 25, 2020Date of Patent: October 4, 2022Assignee: Angion Biomedica Corp.Inventor: Bijoy Panicker
-
Patent number: 11434234Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving elevated levels of aldosterone or abnormal or excessive fibrosis, such as kidney disease and hypertension.Type: GrantFiled: November 23, 2020Date of Patent: September 6, 2022Assignee: Angion Biomedica Corp.Inventors: Bijoy Panicker, Lambertus J. W. M. Oehlen
-
Patent number: 11370783Abstract: The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same.Type: GrantFiled: December 1, 2020Date of Patent: June 28, 2022Assignee: Angion Biomedica Corp.Inventors: An-Hu Li, Satish Kumar Sakilam, Dong Sung Lim
-
Patent number: 10899750Abstract: The present invention provides compositions and formulations of compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein p, R1, R2 and B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of injuries, conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role. In addition, methods are provided for treating such diseases or diseases starting at a time after the onset of the injury, condition or disease.Type: GrantFiled: January 4, 2019Date of Patent: January 26, 2021Assignee: ANGION BIOMEDICA CORP.Inventor: Weizhong Cai
-
Patent number: 10875849Abstract: The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same.Type: GrantFiled: July 29, 2020Date of Patent: December 29, 2020Assignee: ANGION BIOMEDICA CORP.Inventors: An-Hu Li, Satish Kumar Sakilam, Dong Sung Lim
-
Patent number: 10851095Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving elevated levels of aldosterone or abnormal or excessive fibrosis, such as kidney disease and hypertension.Type: GrantFiled: April 30, 2019Date of Patent: December 1, 2020Assignee: ANGION BIOMEDICA CORP.Inventors: Bijoy Panicker, Lambertus J. W. M. Oehlen
-
Publication number: 20200071321Abstract: The present invention provides methods for treating polycystic kidney disease by administering a compound or pharmaceutical composition thereof having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein.Type: ApplicationFiled: July 3, 2019Publication date: March 5, 2020Applicant: ANGION BIOMEDICA CORP.Inventors: Prakash NARAYAN, Brian Huang, Prani Paka, Latha Paka, Itzhak D. Goldberg
-
Publication number: 20200069662Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.Type: ApplicationFiled: August 2, 2019Publication date: March 5, 2020Applicant: ANGION BIOMEDICA CORP.Inventors: Bijoy PANICKER, Rama K. MISHRA, Dong Sung LIM, Lambertus J.W.M. OEHLEN, Dawoon JUNG
-
Patent number: 10556893Abstract: The present invention provides compounds having the general structural formula (I) (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.Type: GrantFiled: May 25, 2018Date of Patent: February 11, 2020Assignee: ANGION BIOMEDICA CORP.Inventor: Bijoy Panicker
-
Patent number: 10414760Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.Type: GrantFiled: November 29, 2016Date of Patent: September 17, 2019Assignee: ANGION BIOMEDICA CORP.Inventors: Bijoy Panicker, Dong Sung Lim, Rama K. Mishra, Lambertus J. W. M. Oehlen, James G. Tarrant, Xiaokang Zhu, Dawoon Jung
-
Publication number: 20190256507Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving elevated levels of aldosterone or abnormal or excessive fibrosis, such as kidney disease and hypertension.Type: ApplicationFiled: April 30, 2019Publication date: August 22, 2019Applicant: ANGION BIOMEDICA CORP.Inventors: Bijoy PANICKER, Lambertus J.W.M. OEHLEN
-
Patent number: 10287282Abstract: The present invention provides compounds having the general structural formula (I) [formula should be inserted here] and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving elevated levels of aldosterone or abnormal or excessive fibrosis, such as kidney disease and hypertension.Type: GrantFiled: December 29, 2015Date of Patent: May 14, 2019Assignee: ANGION BIOMEDICA CORP.Inventors: Bijoy Panicker, Lambertus J. W. M. Oehlen
-
Publication number: 20190125731Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.Type: ApplicationFiled: December 18, 2018Publication date: May 2, 2019Applicant: ANGION BIOMEDICA CORP.Inventors: Bijoy PANICKER, Rama K. MISHRA, Dong Sung LIM, Lambertus J.W.M. OEHLEN, Dawoon JUNG
-
Patent number: 10195184Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.Type: GrantFiled: March 19, 2017Date of Patent: February 5, 2019Assignee: ANGION BIOMEDICA CORP.Inventors: Bijoy Panicker, Rama K. Mishra, Dong Sung Lim, Lambertus J. W. M. Oehlen, Dawoon Jung
-
Publication number: 20180334455Abstract: The present invention provides compounds having the general structural formula (I) (I) and pharmaceutically acceptable derivatives thereof as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.Type: ApplicationFiled: May 25, 2018Publication date: November 22, 2018Applicant: ANGION BIOMEDICA CORP.Inventor: Bijoy Panicker
-
Patent number: 9988374Abstract: The present invention provides compounds having the general structural formula (I) (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.Type: GrantFiled: August 11, 2015Date of Patent: June 5, 2018Assignee: ANGION BIOMEDICA CORP.Inventor: Bijoy Panicker
-
Publication number: 20180148438Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.Type: ApplicationFiled: November 29, 2016Publication date: May 31, 2018Applicant: Angion Biomedica CorpInventors: Bijoy Panicker, Dong Sung Lim, Rama K. Mishra, Lambertus J.W.M. Oehlen, James G. Tarrant, Xiaokang Zhu, Dawoon Jung
-
Publication number: 20180093982Abstract: The present invention provides methods for treating polycystic kidney disease by administering a compound or pharmaceutical composition thereof having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein.Type: ApplicationFiled: April 16, 2017Publication date: April 5, 2018Applicant: ANGION BIOMEDICA CORP.Inventors: Prakash NARAYAN, Brian HUANG, Prani PAKA, Latha PAKA, Itzhak D. GOLDBERG